Age and diagnostic performance of Alzheimer disease CSF biomarkers

OBJECTIVES: Core CSF changes in Alzheimer disease (AD) are decreased amyloid β(1–42), increased total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal degeneration, and tangle pathology, respectively. These biomarkers identify AD already at the predementia stag...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mattsson, N., Rosén, E., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., Herukka, S.-K., van der Flier, W.M., Blankenstein, M.A., Ewers, M., Rich, K., Kaiser, E., Verbeek, M.M., Olde Rikkert, M., Tsolaki, M., Mulugeta, E., Aarsland, D., Visser, P.J., Schröder, J., Marcusson, J., de Leon, M., Hampel, H., Scheltens, P., Wallin, A., Eriksdotter-Jönhagen, M., Minthon, L., Winblad, B., Blennow, K., Zetterberg, H.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2012
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3280049/
https://ncbi.nlm.nih.gov/pubmed/22302554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3182477eed
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados